Tasigna, a common treatment option for patients suffering from Philadelphia chromosome-positive chronic myeloid leukemia (CML), has been linked to atherosclerosis, a serious circulatory condition. Tasigna-related atherosclerosis restricts blood to the heart and other organs which leads to amputations, coronary artery disease (blockage of the arteries), and even death. Novartis, the manufacturer, warned patients and doctors in Canada but has yet to warn consumers in the United States.
If you or a loved one has taken Tasigna and experienced atherosclerosis, amputation, blockage of the arteries, or death, contact your national drug team at GoldenbergLaw. Our Tasigna lawyers can make sure that you are being represented fairly and will hold Novartis responsible.
Case Quick Facts
In 2011, researchers found a link between Tasigna and atherosclerosis. This dangerous life-threatening disease is not warned about on the drug label in the United States, so you and your doctor couldn’t make an informed decision. Atherosclerosis is a disease in which plaque builds up in the arteries, causing the narrowing of the pathways. Narrow arteries limit the blood flow throughout the body and can lead to other diseases and death.
- Heart and vascular bypass surgery
- Amputation of limbs
Novartis became aware of the link between Tasigna and atherosclerosis in 2011. The company added the risk to its warning label in Canada, but not in the U.S. In 2013, Novartis paid $390 million to resolve a Justice Department case in which the company was accused of falsely advertising the drug and illegally giving kickbacks to pharmacies for recommending the drug.
It’s not right that Novartis failed to warn U.S. consumers about the risk of atherosclerosis. Help us hold them accountable. Call us for a free case evaluation. There’s no fee unless we recover for you.
GoldenbergLaw Can Help
Five reasons why GoldenbergLaw can help:
- When it comes to handling a Tasigna atherosclerosis lawsuit, our team is qualified to take on the case wherever you live in the U.S.
- GoldenbergLaw has over 30 years of experience handling defective drug cases and has had a great amount of success throughout those years.
- We are a firm that focuses its practice on drug and device cases.
- We are a national leader in our field and have successfully recovered for thousands of clients.
- We will treat you like family.
If you believe you or a loved one may have been diagnosed with atherosclerosis as a result of Tasigna, please call our Tasigna atherosclerosis lawyers today at 800-504-0281. Leave the sleepless nights to us.
What Is Tasigna?
Tasigna is an oral treatment for patients with CML. It was first approved by the FDA in 2007. Tasigna belongs to a class of drugs called tyrosine kinase inhibitors. Tyrosine kinases are proteins that cause cancer cells to grow. Tasigna and other tyrosine kinase inhibitors work to block the cancer-causing proteins.
Clinical studies have linked Tasigna to atherosclerosis, a cardiovascular disease that causes plaque to build up in the arteries. The plaque causes the arteries to thicken and harden, leaving little room for blood flow. Unfortunately, this can lead to tissue death, limb amputation, coronary artery disease, and even death.
Why Choose GoldenbergLaw?
When it comes to handling a Tasigna atherosclerosis lawsuit, our team is supremely qualified to take on your case. GoldenbergLaw has years of experience working on defective drug and device litigations and has had a great amount of success throughout those years. We treat our clients as if they were our own family. If you have been affected negatively by Tasigna, contact us and get a free consultation. There’s no fee unless we recover.